GRCL — Gracell Biotechnologies Share Price
0.000.00%
Last trade - 00:00- $972.69m
- $750.11m
- 49
- 23
- 90
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.32 | ||
| Price to Tang. Book | 4.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.86% | ||
| Return on Equity | -31.57% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | 0.37 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The Company is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The Company is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- May 22nd, 2018
- Public Since
- January 8th, 2021
- No. of Employees
- 314
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 479,632,139
- Address
- Building 3, SHANGHAI, 200030
- Web
- https://www.gracellbio.com/
- Phone
- +86 2164031522
- Auditors
- PricewaterhouseCoopers Zhong Tian LLP
Upcoming Events for GRCL
Q1 2024 Gracell Biotechnologies Inc Earnings Release
Gracell Biotechnologies Inc Annual Shareholders Meeting
Q2 2024 Gracell Biotechnologies Inc Earnings Release
Similar to GRCL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Gracell Biotechnologies share price?
As of Today at 18:09 UTC, shares in Gracell Biotechnologies are trading at $10.14. This share price information is delayed by 15 minutes.
How has the Gracell Biotechnologies share price performed this year?
Shares in Gracell Biotechnologies last closed at $10.14 and the price had moved by +382.86% over the past 365 days. In terms of relative price strength the Gracell Biotechnologies share price has outperformed the S&P500 Index by +293.49% over the past year.
What are the analyst and broker recommendations for Gracell Biotechnologies?
The overall consensus recommendation for Gracell Biotechnologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Gracell Biotechnologies dividend yield?
Gracell Biotechnologies does not currently pay a dividend.
Does Gracell Biotechnologies pay a dividend?
Gracell Biotechnologies does not currently pay a dividend.
When does Gracell Biotechnologies next pay dividends?
Gracell Biotechnologies does not currently pay a dividend.
How do I buy Gracell Biotechnologies shares?
To buy shares in Gracell Biotechnologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gracell Biotechnologies?
As of the previous close price of $10.14, shares in Gracell Biotechnologies had a market capitalisation of $972.69m.
Where are Gracell Biotechnologies shares listed?
Here are the trading details for Gracell Biotechnologies:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GRCL
What kind of share is Gracell Biotechnologies?
Based on an overall assessment of its quality, value and momentum Gracell Biotechnologies is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gracell Biotechnologies share price forecast for 2024?
The analyst consensus target price for shares in Gracell Biotechnologies is $10.58. That is 4.34% above the last closing price of $10.14.
Analysts covering Gracell Biotechnologies currently have a consensus Earnings Per Share (EPS) forecast of -CNY6.44 for the next financial year.
Find out moreWhat is the trend in the Gracell Biotechnologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gracell Biotechnologies. Over the past six months, its share price has outperformed the S&P500 Index by +168.46%.
As of the last closing price of $10.14, shares in Gracell Biotechnologies were trading +105.71% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gracell Biotechnologies PE Ratio?
The Gracell Biotechnologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gracell Biotechnologies?
We do not have data on Gracell Biotechnologies' directors